Triple fixed combination for asthma patients

Bronchial asthma (BA) is one of the most common respiratory diseases. The primary purpose of BA treatment is to achieve disease control on a case-to-case basis. The disease control concept refers to not only the current control over symptoms, but also the risk of adverse outcomes in the future. Inhaled glucocorticosteroids (ICS) remain the mainstay of treatment for adult patients with AB. Long-acting e2-agonists (LABA) are recommended to all patients who continue to experience symptoms as add-on therapy to medium- or high-dose ICS as the preferred option for controlled treatment at stages 4 and 5. However, despite LABA / ICS therapy, some patients may still exhibit uncontrolled asthma, in which case long-acting anticholinergics (LAMA) should be included in the treatment regimen. Concurrent use of multiple and often different medications poses a significant burden for patients with BA. The presence of LABA / LAMA / ICS in a single inhaler can ensure the best medication adherence in patients with asthma. This therapy option is indicated for patients with persistent asthma uncontrolled with medium- or high-dose ICS + LABA and patients receiving medium- and high-dose ICS / LABA / tiotropium bromide in multiple inhalers. This will enhance BA control, which has been proven in a number of clinical studies. In the clinical case under discussion, a patient with severe BA had to be prescribed a disease-modifying drug in the form of a triple fixed-dose combination in a single inhaler to improve disease control, which led to increased tolerance of physical activities, absence of asthma attacks, shortness of breath, night symptoms, the need for short-acting e2-agonists (SABA), and calls for emergency medical service.